Cytokinetics Awaits Amgen's Phase III Plan After Phase II Heart Drug Success
This article was originally published in Scrip
Executive Summary
Next steps in the development of heart failure drug omecamtiv mecarbil are unclear following the successful conclusion of a Phase II clinical trial while Cytokinetics Inc. waits to determine with partner Amgen Inc. whether the mid-stage data are sufficient to justify investment in a Phase III program.